CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened

CytoMed Therapeutics Limited (NASDAQ:GDTC)’s stock price dropped 13.7% during trading on Tuesday . The company traded as low as $2.77 and last traded at $2.96. Approximately 313,428 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 2,783,089 shares. The stock had previously closed at $3.43.

Analyst Ratings Changes

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of CytoMed Therapeutics in a report on Thursday, October 10th.

CytoMed Therapeutics Price Performance

The business’s fifty day moving average is $2.58 and its two-hundred day moving average is $2.12.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.